Animal Vaccines Market By Product(Attenuated Live Vaccines, Inactivated Vaccines), By Animal Type(Companion Animals, Livestock Animals), By Disease(Anaplasmosis, Canine Parvovirus, Others), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032

Report Overview

Animal Vaccines Market size is expected to be worth around USD 29.0 Bn by 2032 from USD 12.4 Bn in 2022, growing at a CAGR of 9.1% during the forecast period from 2023 to 2032.

Request Covid - 19 Impact

The market for animal vaccines refers to the industry that develops, manufactures, and distributes vaccines intended to prevent maladies in animals. These vaccines are essential for sustaining the health and welfare of numerous species, including livestock, domesticated animals, and untamed animals.

The primary objective of the market for animal vaccines is to prevent diseases in animals by enhancing their immune system's ability to recognize and combat pathogens. This is accomplished by introducing a modified or deceased form of the respective pathogen into an animal's body, thereby stimulating an immune response without causing disease. Vaccines seek to reduce infectious disease-related morbidity and mortality rates, resulting in enhanced animal health and increased productivity.

The significance of vaccines for animals cannot be exaggerated. Vaccines have played a crucial role in the eradication and control of numerous devastating animal diseases across the globe. Vaccines contribute to human health by decreasing the risk of zoonotic diseases, which can be transmitted from animals to humans.

In recent years, the animal vaccines market has witnessed remarkable innovations. Biotechnology and genomics advancements have enabled the creation of novel vaccine platforms and enhanced vaccine efficacy. For instance, the use of recombinant DNA technology has revolutionized vaccine production, enabling the creation of safer, more effective, and less harmful vaccines.

Despite the fact that the market for animal vaccines offers numerous advantages and benefits, it is essential to address ethical issues connected to vaccination practices. Advocates for animal welfare highlight the significance of minimizing pain, distress, and irritation during vaccination procedures. There are efforts to develop non-invasive vaccine delivery methods, such as oral or intranasal vaccines, reducing the need for injections and mitigating animal suffering.

Driving factors

Boosting the Adoption and Ownership of Pets

The market for animal vaccines is expanding rapidly owing to a number of factors. One of these factors is the rising adoption and ownership of pets. There has been a significant increase in the number of households that own canines, cats, and small mammals in recent years. This increase can be attributed to a greater understanding of the psychological and emotional benefits of pet companionship.

Increase in Animal and Bird Farming

The production of livestock and poultry is essential to satisfying the global demand for sustenance products. The need for increased livestock and poultry production becomes evident as the population grows. However, this expansion presents its own set of obstacles, such as the possibility of disease outbreaks among these animal populations.

Increasing Incidence of Zoonotic Diseases

Zoonotic diseases are infectious diseases that can be transmitted between animals and humans. The global prevalence of zoonotic diseases and epidemics, such as avian influenza, rabies, and Ebola vaccine, has caused public health authorities significant concern. In addition to posing a hazard to human health, these maladies have severe economic repercussions.

Vaccine Engineering

The market for animal vaccines has witnessed significant advances in vaccine technology, enabling the creation of more effective and targeted vaccines. For decades, conventional vaccines, such as inactivated and attenuated vaccines, have been extensively utilized. Nonetheless, DNA vaccines, recombinant subunit vaccines, and vector-based vaccines are gaining popularity. These cutting-edge technologies have proved to be extremely effective at preventing animal diseases. DNA vaccines, for example, provide durable immunity and are readily modifiable to combat emergent viral strains.

Increasing Government Programs

Governments around the globe are beginning to recognize the significance of animal health for public health and food security. As a result, they are implementing numerous initiatives and programs to promote animal welfare and prevent the spread of disease. These initiatives range from vaccination requirements and disease surveillance to the promotion of responsible companion ownership and livestock management. As a part of these initiatives, governments frequently collaborate with specialists, research institutions, and pharmaceutical companies to develop and distribute suitable vaccines. This collaborative approach ensures that vaccines for animals are more accessible, affordable, and tailored to the specific requirements of various regions and animal populations.

Welfare of animals and disease prevention

In recent years, society's perception of animals and their welfare has shifted significantly. Individuals, organizations, and governments have deemed animal welfare a top priority. As a result, there is a growing emphasis in the profession on disease prevention and proactive healthcare measures. Vaccinations are essential to animal welfare because they prevent the onset and transmission of maladies. Vaccinations contribute to the overall health and quality of life of animals by keeping them disease-free and healthy. This shift towards a preventative approach is not only beneficial to individual animals, but also contributes to the larger goal of establishing a more humane society.

Restraining Factors

Possible Regulations and Approvals

Regulatory and licensing procedures make creating animal vaccines difficult. The USDA and EMA in the US and Europe approve vaccines, respectively. Before marketing or distributing vaccines, these regulatory authorities check safety, effectiveness, and quality. For vaccination safety and efficacy, the animal vaccines market must follow strict rules. Manufacturers face lengthy and costly testing and assessment in this regulatory environment. Vaccine producers may also face hurdles to entrance due to country-specific legislation, limiting vaccines for numerous animal species globally.

Market Fragmentation

Numerous manufacturers and suppliers serve the animal vaccines market. Fragmentation can affect quality control, standardization, and market rivalry. The results of the test are the same as the results of the test. Multiple market players increase competition, which can affect prices and accessibility. This market fragmentation and rivalry make it difficult for vaccine makers to gain market share and produce high-quality vaccines for many animal species.

Rural Veterinarian Access

Vaccination effectiveness depends on services. Rural regions typically lack clinics or professionals. Geography, infrastructure, or a lack of personnel in rural places might limit accessibility. Rural locations lack services, which might lower animal vaccination rates. Many animal owners lack care and cannot get or administer vaccines, making them more susceptible to infections. To provide rural populations with high-quality services, including vaccination campaigns, infrastructure, training, and outreach initiatives must be improved.

Affordability and Accessibility

Affordability and accessibility of vaccines are key to widespread use. The cost of a new automobile is always a concern, but the cost of a new car is also a factor. Some animal owners may also have trouble getting vaccines, especially in distant or underserved locations. To make critical vaccines available to all animal populations, cost-effective manufacturing methods, inexpensive pricing models, and enhanced delivery networks are needed.

Product Analysis

In 2022, the attenuated live vaccines segment held a significant share of 29.4% in terms of revenue within the product segments. This segment is projected to continue its dominant position over the forecast period.

The high adoption of these vaccines stems from their ability to induce strong cellular and antibody-mediated immune responses. Attenuated vaccines contain live microorganisms that have been weakened under laboratory conditions so they can no longer cause disease but still prompt the immune system to produce antibodies. This type of vaccine provides robust, long-lasting immunity with a single dose compared to other vaccine types that may require boosters. Attenuated animal vaccines are available for major viral diseases like rabies, parvovirus, calicivirus, and distemper.

However, recombinant vaccines are also expected to experience significant growth during this time. Recombinant vaccines are a newer type of vaccine that is produced using genetic engineering techniques. As recombinant vaccine technology continues to develop, it is likely that they will play an increasingly important role in the animal vaccine market.

By Animal Type

The livestock animal segment stands as a dominant force, wielding considerable influence and importance in 2022. This segment primarily caters to animals such as cattle, pigs, sheep, and poultry, which play a pivotal role in global food production, sustenance, and economic stability.

Livestock vaccination is not just about animal welfare but also about safeguarding the global food supply chain. Diseases like foot-and-mouth disease, avian influenza, and swine fever can devastate livestock populations, disrupt the supply of meat, dairy, and other animal-derived products, and even threaten food security. As a result, the livestock animal vaccine segment has become instrumental in preventing and mitigating these outbreaks.

As the world's population continues to grow, ensuring the well-being of livestock animals through effective vaccination becomes increasingly vital for global food security and economic sustainability.

By Disease

Foot & Mouth Disease (FMD) stands out as a dominant concern in the market. This highly contagious viral illness affects cloven-hoofed animals such as cattle, pigs, and sheep. The economic consequences of an FMD outbreak can be devastating, leading to massive losses in the agricultural sector due to reduced productivity, trade restrictions, and culling of infected animals.

The prevalence of FMD underscores the critical need for effective vaccines to prevent its spread. These vaccines play a pivotal role in controlling and mitigating outbreaks, safeguarding both animal welfare and the agricultural economy. The development and distribution of FMD vaccines represent a substantial segment of the animal vaccine market. Researchers and pharmaceutical companies continually strive to improve vaccine formulations to enhance their efficacy and duration of protection.

By Route of Administration

During the year 2022, the subcutaneous segment asserted its dominance by capturing a substantial revenue share exceeding 45%. This trend is anticipated to persist and gain momentum throughout the forecasted period.

Subcutaneous injection into the subcutis layer of skin is advantageous for animal vaccines as it slowly deposits the antigen for a sustained immune response. The loose connective tissue in the subcutis provides a large surface area for absorption. Subcutaneous shots are also relatively quicker and easier to administer compared to intramuscular injections which require identifying a specific muscle site.

The minimal blood flow in the subcutis limits antigen dispersion, keeping it localized near immune cells. Common sites for subcutaneous vaccination in animals include under the neck or leg. The simplicity of administering subcutaneous shots makes this the preferred route for animal owners and veterinarians immunizing pets and production animals. Enabled by the launch of novel pre-filled syringes, the subcutaneous segment will continue experiencing high growth as this injection method provides targeted, safe delivery of antigens for attaining robust immunity.

By Distribution Channel

In 2022, the veterinary hospital pharmacies segment held a notably larger share of the revenue, accounting for over 40%. These pharmacies serve as key intermediaries, ensuring that a wide range of vaccines reaches the hands of veterinarians, pet owners, and livestock producers alike. Their significance extends beyond mere revenue figures, as they contribute significantly to animal health and welfare.

Moreover, the role of veterinary hospital pharmacies extends beyond the mere distribution of vaccines. They serve as knowledge hubs, providing valuable guidance to veterinarians and pet owners alike on vaccination schedules, dosage, and proper administration techniques. Their expertise fosters responsible vaccination practices, ensuring that animals receive the appropriate immunization, thereby reducing the risk of preventable diseases and epidemics.

Key Market Segments

By Product

• Attenuated Live Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vaccines
• DNA Vaccines

By Animal Type

• Companion Animals
  • Canine
  • Avian
  • Feline
• Livestock Animals
  • Aquatic
  • Bovine
  • Porcine
  • Ovine/Caprine
  • Poultry
  • Equine

By Disease

• Anaplasmosis
• Canine Parvovirus
• Foot & Mouth Disease
• New Castle Disease
• Distemper Disease
• Influenza
• Porcine Reproductive & Respiratory Syndrome (PRRS)
• Others

By Route of Administration

• Subcutaneous
• Intramuscular
• Intranasal
• Oral

By Distribution Channel

• Veterinary Clinics
• Veterinary Hospital Pharmacies
• Veterinary Research Institutes
• Retail Pharmacies

Growth Opportunity

R&D and innovation

The animal vaccines market relies on new and better vaccines. Companies may supply breakthrough vaccination solutions for emerging illnesses and problems by investing in R&D. DNA, recombinant, and reverse engineering vaccines have great potential for fighting complicated illnesses and improving effectiveness. To promote cutting-edge research, speed vaccine development, and boost growth, the animal vaccines market must maintain collaborations with academia, research institutes, and governments.

Entering Untapped Markets

animal vaccine makers have tremendous expansion prospects by entering new markets with more pet ownership and livestock output. These regions, including Asia-Pacific, Latin America, and the Middle East, are seeing a growth in pet adoption, urbanization, and economic development, which increases disposable income and animal healthcare spending. Working with local distribution networks, clinics, and animal health groups can assist reach these markets and meet various client demands. Companies may become important players in these high-potential countries and increase revenue by customizing vaccination portfolios and marketing tactics.

Collaborations

The animal vaccines market relies on collaboration with research and animal health organizations. Shared knowledge, resources, and data speed vaccine development, disease surveillance, and preventative treatment. Joint endeavors can accelerate the detection of new illnesses and the development of viable vaccines by sharing scientific information. Strong collaboration between industry, academia, and regulatory agencies helps standardize rules and procedures for vaccines, assuring quality and safety.

Prevention and Companion Animal Vaccines

The animal vaccines market has huge development potential due to customer preferences for preventative care and companion animals. To protect the health and lifespan of their cherished animals, pet owners are now pursuing preventative healthcare methods. Companion animal vaccines, such as those for dogs, cats, and horses, protect their health and prevent infectious disease transmission. Companies should create tailored companion animal vaccines and educate doctors and pet owners about timely immunizations and periodic checkups. Preventive treatment can boost the animal vaccines market and animal welfare.

Latest Trends

Infectious Disease Companion Animal Vaccine Growth

Companion animal vaccines are in demand because people and pets are closer than ever. Pet owners now safeguard their animals against zoonotic illnesses including rabies, parvovirus, and feline leukemia due to increased knowledge. Advanced companion animal vaccines have been developed due to increased awareness. Acclaimed business leads this care revolution. Our researchers and scientists persistently produce unique, highly effective vaccines that target numerous infections. These advances protect companion animals and humans.

For Food Safety and Productivity, Livestock Vaccines

Livestock farmers must balance food safety with animal health and production. Livestock vaccination demand has increased in the animal vaccines market to address these issues. Company pioneered livestock productivity and food safety vaccines via diligent research and development. These vaccines reduce disease outbreaks and farmer losses by fighting common infections. Our unique technologies help farmers increase efficiency and satisfy global food market needs.

DNA and Recombinant Vaccines

DNA and recombinant vaccines changed medicine. These innovative methods have improved animal pathogen prevention. We developed recombinant DNA Technology vaccines using the latest knowledge. These vaccines use genetic engineering to induce a strong immune response for long-term, tailored protection. Veterinarians and pet owners may protect animal health with these revolutionary vaccines.

Increase in One Health Animal Vaccination

In animal vaccination, the One Health concept has grown due to the interdependence of human, animal, and environmental health. This integrative approach protects humans, animals, and the ecosystem. The One Health approach to animal immunization fits nicely with our basic principles, thus we happily endorse it. We help our world survive and thrive by promoting vaccines for humans and animals.

Needle-Free and Oral Vaccines

The way we provide immunizations to animals is changing thanks to the development of new technologies. Needle-free and oral vaccination delivery technologies have gained popularity because they increase animal care, administration, and immunization coverage. We invented needle-free and oral vaccine administration methods for animals and their caregivers via extensive research and development. These approaches remove injection pain, give exact dosages, and boost immunization compliance.

Regional Analysis

North America dominates the market for animal vaccines. In the sphere of animal healthcare, North America is a dominant force in the market for animal vaccines. With its cutting-edge technologies, robust research and development, and in-depth knowledge of market dynamics, North America has carved out a prominent niche. This region has experienced an extraordinary increase in demand for animal vaccines, propelling its market share to unprecedented heights.

The market for animal vaccines in North America is expanding at an unprecedented rate, primarily as a result of the increasing prevalence of animal diseases and pet owners' growing awareness of preventive healthcare measures. Together with stringent regulations and guidelines, the region's proactive approach to animal healthcare has accelerated the adoption of vaccines to safeguard animal populations from various infectious diseases.

The presence of prominent pharmaceutical companies and research institutions dedicated to animal health is a significant factor in North America's dominance in the animal vaccines market. These organizations invest substantial funds in research and development to create innovative and effective vaccines. The region features a robust network of clinics, diagnostic laboratories, and academic institutions that work together to address emergent animal health issues.

The comprehensive approach to animal healthcare in North America extends beyond companion animals to include livestock and poultry. Increasing demand for high-quality animal protein and the need to ensure food safety have fueled the regional livestock industry's expansion. Vaccination is now an integral element of animal management practices in order to protect the health and productivity of livestock.

Key Regions and Countries

North America

• US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

Bayer AG, a global champion in the animal health industry, has made significant advancements in the development and production of animal vaccines. Bayer AG is committed to providing high-quality vaccines that defend animals from a variety of infectious diseases, with a strong emphasis on innovation.

Sanofi, a prominent global pharmaceutical corporation, has a substantial presence in the market for animal vaccines. The company's mission is to improve animal health through the creation of novel vaccines. Sanofi's vaccines are renowned for their safety, efficacy, and ability to provide durable protection against a variety of maladies.

The renowned pharmaceutical company Pfizer Inc. has a substantial presence in the animal vaccines market. With a long history of scientific expertise, Pfizer Inc. is committed to providing innovative animal health solutions.

GSK plc, a global leader in healthcare, has established its presence in the animal vaccines market through its commitment to providing vaccines that safeguard animal health. GSK plc intends to address unmet requirements in the profession by focusing on research-driven innovation.

Merck & Co., Inc., also known as MSD outside of the United States and Canada, dominates the global market for animal vaccines. Merck & Co., Inc., with more than a century of experience in animal health, continues to innovate and develop vaccines that contribute to the global well-being of animals.

Top Key Players in Animal Vaccines Market

• Bayer AG (Germany)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Merck & Co., Inc. (U.S.)
• Ceva (France)
• Cargill, Incorporated (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Takeda Pharmaceutical Company Limited (Japan)
• Zoetis (U.S.)
• Dechra Pharmaceuticals PLC (U.K.)
• Hester Biosciences Limited. (India)
• Elanco (U.S.)
• Phibro Animal Health Corporation (U.S.)
• Indovax (India)

Recent Development

• In 2022, Zoetis acquires Abaxis to strengthen diagnostics business. In a major acquisition deal worth $2 billion, Zoetis, a prominent player in animal health, acquired Abaxis. This strategic move aimed to expand Zoetis' presence in the diagnostics sector.
• In 2021, Merck Animal Health launches Truforma platform for rapid diagnostics. Merck Animal Health made significant strides in the diagnostic field by introducing its Truforma platform. This innovative technology equips veterinarians with rapid diagnostic capabilities for a wide range of animal diseases.
• In 2017, Boehringer Ingelheim's acquisition of Merial expands animal vaccines market. In a pivotal move, Boehringer Ingelheim acquired Merial, a leading player in the animal vaccines market. This acquisition propelled Boehringer Ingelheim to establish its position as a dominant force in the industry.
• In 2020, Virbac introduces VaxiVet range to protect dogs and cats. pharmaceutical company, Virbac, launched its innovative VaxiVet range of vaccines. Designed to safeguard dogs and cats from various diseases, these vaccines offer crucial protection against prevalent or emerging threats.

Report Scope: